

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>BIOGEN IDEC INC</u>  (Last) (First) (Middle) <u>14 CAMBRIDGE CENTER</u>  (Street) <u>CAMBRIDGE MA 02142</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>TARGETED GENETICS CORP /WA/ [ TGEN ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>07/25/2005</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year) <u>07/27/2005</u>	6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, \$0.01 Par Value	07/25/2005		s		8,500	D	\$0.79	11,966,948 <sup>(1)</sup>	I	by Biogen Idec MA, Inc. <sup>(2)</sup>
Common Stock, \$0.01 Par Value	07/26/2005		s		2,500	D	\$0.81	11,964,448 <sup>(1)</sup>	I	by Biogen Idec MA, Inc. <sup>(2)</sup>
Common Stock, \$0.01 Par Value	07/26/2005		s		12,500	D	\$0.82	11,951,948 <sup>(1)</sup>	I	by Biogen Idec MA, Inc. <sup>(2)</sup>
Common Stock, \$0.01 Par Value	07/26/2005		s		10,640	D	\$0.83	11,941,308 <sup>(1)</sup>	I	by Biogen Idec MA, Inc. <sup>(2)</sup>
Common Stock, \$0.01 Par Value	07/26/2005		s		11,200	D	\$0.85	11,930,108 <sup>(1)</sup>	I	by Biogen Idec MA, Inc. <sup>(2)</sup>
Common Stock, \$0.01 Par Value	07/26/2005		s		25,660	D	\$0.86	11,904,448 <sup>(1)</sup>	I	by Biogen Idec MA, Inc. <sup>(2)</sup>
Common Stock, \$0.01 Par Value	07/26/2005		s		2,500	D	\$0.87	11,901,948 <sup>(1)</sup>	I	by Biogen Idec MA, Inc. <sup>(2)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	V	A	D	Date Exercisable (Month/Day/Year)	Expiration Date (Month/Day/Year)	Title	Amount of Shares	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
BIOGEN IDEC INC															
(Last)		(First)	(Middle)												
14 CAMBRIDGE CENTER															
(Street)															
CAMBRIDGE	MA		02142												
(City)	(State)		(Zip)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

1. Name and Address of Reporting Person\*

**BIOGEN IDEC MA INC**

---

(Last) (First) (Middle)

14 CAMBRIDGE CENTER

---

(Street)

CAMBRIDGE MA 02142

---

(City) (State) (Zip)

**Explanation of Responses:**

- This amendment to the Form 4 originally filed on July 27, 2005 (the "Original Form 4") amends and restates the Original Form 4 in its entirety and is being filed solely to correct the amount of Targeted Genetics Corporation common stock beneficially owned by the reporting person. The Original Form 4 inadvertently overreported the reporting person's beneficial ownership of Targeted Genetics Corporation common stock by 25,000 shares.
- Shares are owned indirectly by Biogen Idec Inc. and directly by its wholly-owned subsidiary Biogen Idec MA Inc., fka Biogen, Inc.

**Remarks:**

Raymond G. Arner, Acting  
General Counsel, Biogen Idec 07/29/2005  
Inc.  
Michael F. Phelps, Treasurer, 07/29/2005  
Biogen Idec MA, Inc.  
 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  
 \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).  
 \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).  
 Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.  
 Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.